Loading
Life sciences · Journal article
Diabetology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Observations described as paradoxical are common in diabetes: intensive glucose lowering may fail to improve macrovascular outcomes; long-term benefit may persist after HbA1c convergence; SGLT2 inhibitors can cause an early eGFR dip despite kidney protection; ketoacidosis may occur without marked hyperglycaemia; and contrasting GIP receptor strategies can coexist with effective GLP-1-based therapy. We conducted a structured narrative review of PubMed/MEDLINE literature updated to 8 September 2026, prioritising randomised trials, meta-analyses, consensus statements, and human mechanistic evidence. We propose a two-level framework for interpreting these observations. At the biological level, apparent contradictions arise from time, clinical context, and system complexity. At the measurement and inference level, dynamic and heterogeneous biology may be compressed into snapshots, thresholds, aggregate estimates, or simplified representations of biological state. The framework is applied to intensive glycaemic control and metabolic memory, early retinopathy worsening and treatment-induced neuropathy, SGLT2-associated eGFR change and euglycaemic ketoacidosis, multi-receptor pharmacology, HbA1c in advanced kidney disease, the obesity paradox, and statin-associated dysglycaemia. These phenomena do not share a single biological mechanism. Rather, they illustrate how interpretation can become misleading when relevant temporal, contextual, systems-level, or representational information is omitted, or when biomarkers, mechanisms, surrogates, prediction, and patient-relevant outcomes are treated as interchangeable evidential roles.